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resistant rickets type IIA, a compound heterozygote 
for mutations in the Vitamin D receptor gene (VDR) 
in which the phenotype of atrichia with papular 
lesions was identical to that seen in patients carrying 
mutations in the HR gene. It is hypothesized that 
the VDR and HR genes, which are both zinc-finger 
proteins, may be in the same genetic pathway that 
controls postnatal cycling of the hair follicle.[4]
Yip et al.[5] proposed revised clinical criteria for APL 
based on their personal observation and have made a 
retrospective analysis of cases described in literature. 
These features are listed in Table 1.
Published estimates of the prevalence of APL remain 
surprisingly low, considering that pathogenetic 
mutations in HR have been found in distinct 
populations around the world.[2] APL is more common 
than previously thought and is often mistaken for the 
putative autoimmune form of alopecia universalis.[5]
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Treatment of severe nail 
psoriasis with etanercept
Sir, 
Nail involvement is common in psoriasis and has 
been reported to occur in up to 50% of patients.[1] It 
can cause significant physical impairment, severe 
distress and pain.[1,2] There is a broad spectrum of 
nail dystrophies associated with psoriasis, ranging 
from the common pitting and loosening of the nail 
plate to the less frequent discoloration and splinter 
hemorrhages seen in the nail bed.[1] It is frequently 
refractory to treatment and there is no standardized 
therapy regimen.[3] Etanercept is a fully humanized, 
soluble tumor necrosis factor (TNF)-alpha receptor 
approved for the treatment of plaque psoriasis. It has 
been shown to be safe and to have long-term efficacy 
for treatment of moderate to severe psoriasis resistant 
to other modes. Some reports show that etanercept may 
have significant benefit in the treatment of psoriatic 
nail disease, although not approved for its treatment 
(as only manifestation).[1-4]
Table 1: Diagnostic criteria for APL
Major criteria (4 out of 5 required for diagnosis)
1. Permanent and complete absence of scalp hair by the first few 
months of life
2. Few to widespread smooth, whitish, or milia-like papules on 
the face, scalp, arms, elbows, thighs or knees from infancy or 
childhood
3. Replacement of mature hair follicle structures by follicular cysts 
filled with cornified material in scalp histology
4. Mutation(s) in the human hairless gene through genetic testing
5. Clinical and/or molecular exclusion of vitamin D dependent 
rickets
Minor criteria (supplementary criteria)
1. Family history of consanguinity
2. Absence of secondary axillary, pubic, or body hair growth and/
or sparse eyebrows and eyelashes
3. Normal growth and development, including normal bones, 
teeth, nails and sweating
4. Whitish-hypopigmented streaks on the scalp
5. Lack of response to any treatment modality
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We describe two cases of improvement of nail 
psoriasis with etanercept treatment. The severity of 
nail psoriasis was based on the Nail Psoriasis Severity 
Index (NAPSI).[5] 
Case 1: A 59-year-old man with a 25-year history 
of plaque psoriasis, who after one episode of 
erythroderma and several systemic therapies (acitretin, 
methotrexate, cyclosporine), entered stabilization of 
the disease with Psoriasis Area Severity Index (PASI): 5 
for the last 13 years. He was referred to our department 
because of severe nail psoriasis that was causing 
psychological distress. There was no improvement 
with topical application and intralesional injection of 
corticosteroids. All fingernails had psoriatic lesions 
(onycholysis, subungual hyperkeratosis, pitting 
and leukonychia) with NAPSI: 56. No symptoms 
of psoriatic arthritis were present. He was put on 
etanercept 50 mg twice a week (12 weeks), followed 
by etanercept 50 mg once a week (36 weeks), with 
NAPSI: 4 at week 48 (improvement of 92.9% of the 
nails’ alterations) [Figure 1].
Case 2: A 43-year-old man with a 15-year history of 
plaque psoriasis recalcitrant to traditional systemic 
therapies was put on efalizumab, with significant 
clinical improvement of cutaneous psoriasis. After 20 
months of efalizumab administration, he had PASI:1 
but maintained onycholysis, subungual hyperkeratosis 
and pitting of all fingers (NAPSI: 53). No symptoms of 
psoriatic arthritis were noted. We decided to switch 
from efalizumab to etanercept 50 mg twice a week. At 
week 12, he was placed on a regimen of etanercept 25 
mg twice a week. A significant improvement in nail 
psoriasis was noted after 1 year of etanercept treatment, 
with NAPSI: 30 at week 48 (56.6% improvement of the 
nail psoriasis) [Figure 2].
In both the patients, treatment was monitored closely. 
No side effects were present.
Recent studies have revealed that joint pain and nail 
psoriasis are responsible for impairment in quality of 
life. Etanercept therapy provided rapid improvement 
among patients with nail symptoms at baseline.[4]
In our two cases, the patients had been treated with 
several systemic therapies for psoriasis without 
improvement of nail manifestations. At week 48 of 
etanercept treatment, a good response was obtained 
with NAPSI improvement (92.9% and 56.6%, 
Figure 1: (a–c) NAPSI: 56 at week 0 of treatment with etanercept; 





Figure 2: (a–c) NAPSI: 53 at week 0 of treatment with etanercept; 





respectively). Both the patients were very much 
satisfied with the outcome.
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Dactylitis as a first manifestation 
of arthritis associated with 
hidradenitis suppurativa
Sir, 
Dactylitis or “sausage digit” is a typical manifestation 
of spondyloarthropathy (SpA)[1] and it is so specific 
to SpA that it was included among the classification 
criteria of the whole disease group.[2] Dactylitis may 
sometimes occur alone for a long time as the only 
clinically manifestation of the SpA.[1]
We report here a patient with hidradenitis suppurativa 
(HS) in whom dactylitis occurred 2 years prior to the 
onset of a seronegative arthritis.
In October 2005, a 50-year-old Caucasian woman with 
a 10-year history of HS presented to the Dermatology 
Clinic with multiple pustules, nodules, abscesses, and 
cystic lesions in the axillary, mammary, and inguinal 
regions [Figure 1]. Furthermore, she complained 
of severe swelling and pain of the third finger of 
her left hand of 3 months duration. Her family 
history was negative for SpA and other HLA B27-
associated diseases. There was no history of trauma, 
psoriasis, diarrhea, sexually transmitted diseases, 
conjunctivitis, iritis, uveitis, mucosal ulceration, 
Raynaud’s phenomenon, sarcoidosis or gout. Clinical 
examination showed a swelling affecting the entire 
third finger of her left hand so pronounced that 
the patient could not flex it, and the presence of 
Heberden's nodules [Figure 2]. Laboratory studies 
showed an Erythrocyte Sedimentation Rate (ESR) 
of 101 mm/hour in the first hour, C-reactive protein 
(CRP) of 6.21 mg/dl, and a white blood cell count of 
8.5 × 103/mm3. Rheumatoid factor (RF), antinuclear 
(ANA) and anti-cyclic citrullinated peptide (anti-
CCP) antibodies, circulating immune-complexes 
(CIC), angiotensin converting enzyme, HLA-B27 
and HLA-DR4 antigens were normal or negative. 
Blood, urine and fecal cultures were negative, whilst 
Figure 1: Hidradenitis suppurativa: Evidence of nodules and cystic 
lesions in the left axillary region
Figure 2: Dactylitis: Evidence of severe swelling of the third finger 
of the left hand; as a collateral finding, we point out the presence 
of Heberden nodules on the second, fourth and fifth fingers
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